Joint Pain Injections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others), By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.72 Billion
CAGR (2026-2031)	7.76%
Fastest Growing Segment	Spinal Joints,
Largest Market	North America
Market Size (2031)	USD 7.39 Billion

Market Overview

The Global Joint Pain Injections Market will grow from USD 4.72 Billion in 2025 to USD 7.39 Billion by 2031 at a 7.76% CAGR. Joint pain injections are therapeutic interventions involving the administration of analgesic or anti-inflammatory agents directly into the synovial space to alleviate musculoskeletal discomfort and improve mobility. The market is primarily driven by the globally aging population and the increasing prevalence of osteoarthritis which necessitates effective non-surgical pain management solutions. According to Arthritis UK, in 2025, over 10 million people in the United Kingdom were living with arthritis. This data underscores the critical demand for symptomatic relief therapies that serve as a vital bridge between oral medication and invasive surgical procedures.

Nevertheless, the market faces a substantial impediment regarding the safety profile associated with the long-term use of intra-articular corticosteroids. Repeated administration can lead to adverse effects such as cartilage degradation or joint infection which often deters sustained clinical adoption. This risk factor compels healthcare providers to limit usage frequency and presents a notable challenge to the consistent expansion of the injection therapy sector.

Key Market Drivers

Increasing Prevalence of Osteoarthritis and Rheumatoid Arthritis acts as the primary catalyst for the Global Joint Pain Injections Market. As the global population ages, the burden of degenerative joint diseases intensifies and creates a sustained demand for non-surgical symptomatic relief. This demographic shift forces healthcare systems to prioritize injectable therapies such as corticosteroids and hyaluronic acid to manage pain and delay invasive surgeries like total knee arthroplasty. According to the Centers for Disease Control and Prevention (CDC), June 2025, in the 'Preventing Chronic Disease' report, the overall crude prevalence of diagnosed arthritis among adults aged 20 years or older in the United States reached 27.9%. This staggering volume of patients underscores the critical need for effective intra-articular treatments to maintain workforce productivity and quality of life.

Surging Global Obesity Rates Accelerating Joint Degeneration further propels market expansion by significantly lowering the average age of arthritis onset. Excess body weight places immense mechanical stress on weight-bearing joints and accelerates cartilage breakdown which necessitates earlier therapeutic intervention. According to the World Obesity Federation, March 2025, in the 'World Obesity Atlas 2025', the organization projected that the total number of adults living with obesity globally would rise to 1.13 billion by 2030. This trend directly correlates with increased incidents of musculoskeletal comorbidities and drives pharmaceutical developers to expand their pain management portfolios. Consequently, according to Anika Therapeutics, in 2025, revenue for its Commercial Channel driven by international osteoarthritis pain management products increased by 17% in 2024 compared to the previous year.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the global joint pain injections market is the safety concern associated with the long-term use of intra-articular corticosteroids. While these agents provide effective temporary relief, their sustained administration is restricted by risks such as cartilage degradation and joint infections. Consequently, healthcare professionals are compelled to limit the frequency of treatments, often restricting patients to a strict quota of injections annually. This safety ceiling prevents the therapy from becoming a continuous management solution for chronic pain, thereby capping the potential revenue volume per patient and reducing overall market penetration relative to oral analgesics which can be administered daily without similar procedural limits.

This restriction is particularly impactful given the massive patient population that requires consistent pain management. According to the Centers for Disease Control and Prevention, in 2025, 21.3% of adults in the United States had diagnosed arthritis. This data highlights a vast demographic seeking relief; however, the inability to safely administer corticosteroid injections on a frequent basis creates a significant bottleneck in service delivery. The disparity between the high prevalence of the condition and the restricted usage frequency of the treatment directly impedes the market from fully capitalizing on the demand for effective musculoskeletal therapies.

Key Market Trends

The Adoption of Regenerative Medicine and Orthobiologics is reshaping the market as clinicians increasingly prioritize tissue repair over temporary symptom management. This trend is characterized by the integration of biologic solutions, such as hyaluronic acid-based scaffolds and platelet-rich plasma, which aim to restore damaged cartilage and delay joint replacement surgeries. Healthcare providers are rapidly incorporating these therapies into treatment protocols to address the underlying causes of joint degeneration rather than merely masking pain. According to Anika Therapeutics, November 2025, in the 'Third Quarter 2025 Financial Results', revenue for the company's Regenerative Solutions segment increased by 25% during the quarter, driven largely by the market outperformance of the Integrity Implant System and the strong international adoption of Hyalofast.

A concurrent Shift Toward Single-Injection Viscosupplementation Regimens is gaining significant traction due to the demand for patient convenience and reduced clinical burden. Unlike traditional multi-injection courses that require repeated hospital visits, single-injection high-molecular-weight hyaluronic acid formulations offer sustained therapeutic benefits with a unified administration. This approach improves patient compliance and operational efficiency for medical practices, making it a preferred option for managing knee osteoarthritis. According to Bioventus, November 2025, in the 'Third Quarter Financial Results', global revenue for the Pain Treatments segment accelerated by 6.4%, primarily fueled by the strong U.S. demand for Durolane, a differentiated single-injection hyaluronic acid therapy.

Segmental Insights

The spinal joints segment is identified as the fastest-growing area within the global joint pain injections market. This rapid expansion is principally driven by the increasing prevalence of chronic lower back pain and intervertebral disc disorders among the aging population. Patients and healthcare providers increasingly favor these minimally invasive procedures over complex surgeries to manage spinal discomfort effectively. Additionally, consistent product approvals by regulatory authorities such as the U.S. Food and Drug Administration enhance clinical confidence in these treatments, thereby securing higher adoption rates and supporting substantial market progress.

Regional Insights

North America maintains a dominant position in the global joint pain injections market due to the rising incidence of osteoarthritis and an expanding aging population. This leadership is reinforced by comprehensive healthcare coverage and reimbursement policies established by the Centers for Medicare & Medicaid Services, which facilitate patient access to treatments. Furthermore, the region benefits from the concentration of major pharmaceutical manufacturers and distinct regulatory pathways defined by the U.S. Food and Drug Administration. These factors collectively ensure the widespread availability and adoption of therapeutic injection options across the United States and Canada.

Recent Developments

• In November 2024, Pacira BioSciences, Inc. reported new findings from a Phase 1 study of its gene therapy candidate, PCRX-201, for the treatment of osteoarthritis of the knee. The data revealed that the locally administered therapy provided sustained improvements in knee pain, stiffness, and function for 104 weeks following a single intra-articular injection. The company stated that the therapy, which is designed to produce a natural anti-inflammatory protein directly at the site of disease, exhibited a well-tolerated safety profile. This development was cited as a significant step toward providing a durable, disease-modifying treatment option for patients with moderate to severe knee osteoarthritis.
• In September 2024, Sun Pharmaceutical Industries Ltd. and its partner Moebius Medical announced that the U.S. Food and Drug Administration granted Fast Track designation to their investigational therapy, MM-II, for the treatment of osteoarthritis knee pain. The non-opioid product candidate utilizes a proprietary suspension of liposomes designed to lubricate the joint, reduce friction, and provide pain relief. The companies noted that this regulatory designation would facilitate frequent interactions with the agency and potentially expedite the review process as they prepared to advance the therapy into Phase 3 clinical development to address the unmet needs of patients with this degenerative joint disease.
• In September 2024, Contura Orthopaedics Ltd presented new long-term data regarding its novel hydrogel injection, Arthrosamid, at the European Orthopaedic Research Society meeting. The four-year results from the company’s study demonstrated that a single intra-articular injection of the non-biodegradable polyacrylamide hydrogel maintained a statistically significant reduction in pain for patients with knee osteoarthritis. The company emphasized that these findings reinforced the durability of the treatment, which is designed to integrate with the synovial tissue to cushion the joint, offering a sustained alternative to conventional therapies for patients seeking long-lasting pain relief without immediate surgery.
• In May 2024, Organogenesis Holdings Inc. announced positive topline results from its Phase 3 clinical trial evaluating the safety and efficacy of ReNu for the management of knee osteoarthritis symptoms. The cryopreserved amniotic suspension allograft, which is administered via intra-articular injection, met its primary endpoint by demonstrating a statistically significant reduction in knee pain at six months compared to a saline control. The company highlighted that the study also showed significant maintenance of function in the treated patients. These results were described as a milestone in the development of the therapy, positioning it as a potential non-surgical option for patients suffering from moderate to severe osteoarthritis.

Key Market Players

• Anika Therapeutics Inc
• Bioventus LLC
• Ferring Pharmaceuticals Inc
• Sanofi SA
• Pfizer Inc
• Eli Lilly & Co
• Flexion Therapeutics Inc
• Teva Pharmaceutical Industries Ltd
• Zimmer Biomet Holdings, Inc.

By Type of Injection	By Application	By Region
Steroid Joint Injections Hyaluronic Acid Injections Platelet-rich Plasma (PRP) Injections Placental Tissue Matrix (PTM) Injections Others	Shoulder & Elbow Knee & Ankle Spinal Joints Hip Joint Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Joint Pain Injections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Joint Pain Injections Market, By Type of Injection:

• Steroid Joint Injections
• Hyaluronic Acid Injections
• Platelet-rich Plasma (PRP) Injections
• Placental Tissue Matrix (PTM) Injections
• Others

• Joint Pain Injections Market, By Application:

• Shoulder & Elbow
• Knee & Ankle
• Spinal Joints
• Hip Joint
• Others

• Joint Pain Injections Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE